INTRODUCTION AND OBJECTIVES:
The tumor microenvironment is a key component of cancer growth, dissemination and metastasis. Tumor-associated macrophages (TAMs) are the most notable orchestrators in the tumor microenvironment and are involved in each step of cancer progression. However, the precise mechanism underlying TAM-induced lymph node (LN) metastasis remains largely unknown.
METHODS: In situ hybridization and immunochemistry were used to determine LNMAT1 expression in bladder cancer cell lines, clinical tissues and 266 clinicopathologically characterised bladder cancer specimens. The role of LNMAT1 in lymphangiogenesis and lymphatic metastasis was examined by tube formation and cell invasion assays in vitro, and by a popliteal lymph node metastasis model in vivo.
RESULTS: We demonstrate that a novel long noncoding RNA (lncRNA), termed Lymph Node Metastasis Associated Transcript 1 (LNMAT1), is markedly upregulated in LN-positive bladder cancer and significantly associated with LN metastasis and poor prognosis in bladder cancer patients. Mechanistically, LNMAT1 epigenetically upregulates CCL2 expression by promoting H3K36 trimethylation of the CCL2 promoter via interactions with heterogeneous nuclear ribonucleoprotein L. Moreover, LNMAT1-induced CCL2 expression by bladder cancer cells facilitates the infiltration of TAMs, which participate in the pro-lymphangiogenic process of VEGF-C upregulation in bladder cancer, ultimately resulting in lymphangiogenesis and lymphatic metastasis. Importantly, the inhibition of TAM recruitment using a CCL2-neutralizing antibody dramatically reduces LNMAT1-induced LN metastasis in vivo.
CONCLUSIONS: These findings provide novel mechanistic and translational insight into the lncRNA-mediated modulation of the tumor microenvironment that promotes the lymphatic metastasis of bladder cancer.
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Gian Maria Busetto*, Francesco Del Giudice, Paola Gazzaniga, Ettore De Berardinis, Roma, Italy INTRODUCTION AND OBJECTIVES: Management of high-risk NMIBC can be challenging as current methods of prediction are inadequate and an accurate estimation of the outcome risk in the individual patient would help identifying the most appropriate therapy to avoid tumor progression.Although mainly involved in inhibition of apoptosis and regulation of cell cycle, survivin is emerging as a multifunctional molecule, able to support angiogenesis, metastasis and chemo-resistance of tumor cells and to promote survival of cancer stem cells. The expression of survivin in circulating tumor cells (CTCs) might interpreted as a mechanism by which a subset of cancer cells that escape from primary tumor protect themselves from the hostile environmental conditions in the blood, via resistance to apoptosis, and from the attack from the host immune system, via resistance to cytotoxic T-cells mediated lysis. There is reliable evidence that the detection of CTCs is a powerful predictor for unfavorable outcomes in bladder cancer patients. Particularly, evidence has been provided that the presence of CTCs has an independent prognostic value in high-risk non-muscle invasive bladder cancer and possibly identify patients with micrometastatic disease. Long term follow-up study to evaluate the impact on disease free survival and cancer specific survival of survivin expression in tissue and CTCs from T1G3 bladder cancer patients.
METHODS: The study was conducted using tumor tissue and blood samples from 54 patients with a primary diagnosis of T1G3 NMIBC. Survivin was evaluated by reverse transcription-polymerase chain reaction in tumor tissues. CTCs were isolated from blood by CELLectionTM Dynabeads (Invitrogen, Carlsbad, CA, USA). Cells were lysed and cDNA was synthesized and analysed for the expression of CD45, CK8 and survivin. The endpoints of this long-termanalysis were disease-free survival, DFS and cancer specific survival, CSS.
RESULTS: Here we report that, at 9 years of median follow-up, disease free survival and cancer specific survival are both significantly influenced by the expression of survivin in tumor tissue (p¼0.006), by the presence of CTCs (p<0.0001) and by the expression of survivin in CTCs (p<0.0001).
CONCLUSIONS: The statistically significant impact of survivin expressing CTCs on cancer specific survival that we observed might be interpreted as the result of the persistence of a subpopulation of highlander cells in the blood of T1G3 bladder patients over time.
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